Did DEVOTE prove degludec is better for the heart than glargine?

No. DEVOTE proved non-inferiority, meaning degludec is not worse for cardiovascular outcomes. The point estimate favored degludec (HR 0.91) but did not reach statistical significance for superiority (p = 0.21). The trial's primary value is confirming cardiovascular safety and demonstrating hypoglycemia reduction.

How much did nocturnal hypoglycemia decrease with degludec?

Severe nocturnal hypoglycemia was 53% lower with degludec vs. glargine U100 (HR 0.47, 95% CI 0.31, 0.73). This was a pre-specified secondary endpoint with strong adjudication.

Does DEVOTE apply to type 1 diabetes patients?

DEVOTE enrolled only type 2 diabetes patients with cardiovascular risk factors. Separate studies (such as the SWITCH trials) examined hypoglycemia in type 1 diabetes with degludec, but DEVOTE's MACE findings cannot be extrapolated to T1D.

Is degludec better than glargine U300 (Toujeo)?

DEVOTE compared degludec to glargine U100 only. The CONCLUDE trial compared degludec to U300 directly and found no significant difference in severe hypoglycemia. DEVOTE does not establish degludec superiority over second-generation glargine.

Which guidelines changed because of DEVOTE?

The 2018 ADA/EASD consensus report, 2019 ESC/EASD guidelines, and NICE TA321 all incorporated DEVOTE findings. They recommend second-generation basal insulins when hypoglycemia is a clinical concern.

How long did DEVOTE follow patients?

Median follow-up was 1.99 years. The trial was event-driven (requiring 633+ MACE events) rather than time-driven, so duration reflects event accrual rather than a fixed observation period.

Were patients in DEVOTE on GLP-1 receptor agonists or SGLT2 inhibitors?

Yes. Background therapy was open-label and could include any glucose-lowering agent except other basal insulins. The trial did not mandate or restrict GLP-1 RA or SGLT2i use, so results reflect real-world polypharmacy.

What was the severe hypoglycemia rate overall in DEVOTE?

Severe hypoglycemia (any time) occurred at a rate of 40% lower with degludec (HR 0.60, 95% CI 0.48, 0.76). This is a clinically meaningful reduction in a population already at high baseline risk.

Should stable patients on glargine U100 switch to degludec based on DEVOTE?

Not automatically. DEVOTE supports switching when a patient has documented recurrent hypoglycemia, especially nocturnal events, or when cardiovascular safety reassurance influences the prescribing decision. Stable patients without hypoglycemia issues have no trial-based reason to switch.

Did degludec require lower doses than glargine in DEVOTE?

Degludec patients used marginally lower mean doses (0.6 vs. 0.7 U/kg), but this difference was not statistically significant in pre-specified analyses and should not be used for cost modeling.

What DEVOTE Actually Changes in Clinical Practice

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for What DEVOTE Actually Changes in Clinical Practice Image: HealthRX.com clinical image

What DEVOTE Actually Changes in Clinical Practice

At a glance

| Parameter | Detail | |-----------|--------| | N | 7,637 | | Intervention | Insulin degludec (Tresiba) once daily | | Comparator | Insulin glargine U100 (Lantus) once daily | | Duration | Median 1.99 years | | Primary endpoint | Time to first MACE (CV death, non-fatal MI, non-fatal stroke) | | Key result | HR 0.91 (95% CI 0.78, 1.06); non-inferiority confirmed. Severe nocturnal hypoglycemia 53% lower with degludec |

Why DEVOTE Was Necessary

The 2008 FDA guidance mandating cardiovascular outcomes trials (CVOTs) for diabetes drugs created a new class of evidence. Before DEVOTE, no large randomized trial had directly compared two basal insulins on hard cardiovascular endpoints. Observational data and smaller studies suggested degludec's ultra-long half-life (approximately 25 hours) produced flatter pharmacokinetic profiles. But flatter profiles and fewer hypoglycemic episodes in phase 3 trials do not guarantee cardiovascular safety in a population already burdened by atherosclerotic disease.

The FDA initially rejected degludec's US approval in 2013, specifically requesting a dedicated CVOT. DEVOTE was designed to answer that regulatory question and, by extension, a clinical one: does the hypoglycemia reduction translate into a signal that matters for patients with established or high-risk cardiovascular disease?

Methodology Notes Beyond the Abstract

DEVOTE was an event-driven, double-blind, treat-to-target trial. Investigators titrated both arms to the same fasting glucose goal (<90 mg/dL), which is critical to interpretation. Any difference in hypoglycemia emerged despite equivalent glycemic targets, not because of looser control in one arm.

Randomization was stratified by site and insulin status at screening (insulin-naive vs. insulin-treated). Roughly 85% of participants were already on insulin. The population was genuinely high-risk: 85.7% had established cardiovascular disease, median age was 65 years, and mean baseline HbA1c was 7.6% in both groups (Marso et al., NEJM 2017).

The trial required 633 first MACE events for 80% power to establish non-inferiority at a margin of 1.3. This is the same margin used in LEADER, SUSTAIN-6, and other diabetes CVOTs. The study accumulated 649 adjudicated events.

One design choice clinicians should note: concomitant therapy was open-label and could include any glucose-lowering agents except other basal insulins. Background GLP-1 receptor agonist or SGLT2 inhibitor use was permitted but not mandated, so the population reflects a range of modern regimens.

Results That Matter for Prescribing

Primary Endpoint

MACE occurred in 8.5% of the degludec group vs. 9.3% of the glargine group (HR 0.91, 95% CI 0.78, 1.06, p < 0.001 for non-inferiority). The upper bound of 1.06 fell well below the pre-specified 1.3 margin. Superiority was not demonstrated (p = 0.21).

| Component | Degludec (n/%) | Glargine (n/%) | HR (95% CI) | |-----------|---------------|----------------|-------------| | CV death | 2.7% | 2.7% | 0.96 (0.76, 1.21) | | Non-fatal MI | 4.0% | 4.6% | 0.85 (0.68, 1.06) | | Non-fatal stroke | 2.4% | 2.7% | 0.90 (0.68, 1.18) | | All-cause death | 4.6% | 4.8% | 0.95 (0.79, 1.13) |

Hypoglycemia: The Differentiation Signal

Severe hypoglycemia (requiring external assistance): HR 0.60 (95% CI 0.48, 0.76) favoring degludec. Severe nocturnal hypoglycemia: HR 0.47 (95% CI 0.31, 0.73), a 53% relative reduction.

These findings came from a population already at high glycemic target, using validated adjudication. The nocturnal signal is consistent with degludec's pharmacokinetic profile: less peak-to-trough variability means fewer glucose nadirs during sleep.

HbA1c and Dosing

Both arms achieved similar HbA1c reductions (estimated treatment difference 0.01%, NS). Degludec patients used slightly lower doses (mean 0.6 U/kg vs. 0.7 U/kg), though this did not reach clinical significance for cost calculations per the trial's pre-specified analysis (Marso et al., 2017).

What Actually Changed After Publication

Guideline Updates

The 2018 ADA/EASD consensus report incorporated DEVOTE's findings into a recommendation that second-generation basal insulins (degludec, glargine U300) be preferred over NPH or first-generation analogs when hypoglycemia is a concern. The 2022 and subsequent ADA Standards of Care maintain this positioning.

The 2019 ESC/EASD cardiovascular disease and diabetes guidelines cited DEVOTE as evidence that degludec meets cardiovascular safety requirements without a signal of harm.

FDA Label and Regulatory Consequences

Degludec's US label was updated to include DEVOTE data, specifically the MACE non-inferiority finding and the hypoglycemia reduction. The Tresiba prescribing information now includes a dedicated Clinical Studies section describing DEVOTE results. This label update removed any residual regulatory overhang from the original 2013 Complete Response Letter.

Formulary and Prescribing Shifts

In practice, DEVOTE gave pharmacy and therapeutics committees data to justify degludec coverage for patients with recurrent hypoglycemia or established cardiovascular disease. Before DEVOTE, cost discussions around degludec lacked a hard-endpoint trial. After DEVOTE, the conversation shifted from "is it safe?" to "is the hypoglycemia reduction worth the incremental cost?"

Several large US health systems moved degludec to preferred status specifically for patients with documented severe hypoglycemia episodes. The UK's NICE Technology Appraisal (TA321, updated 2018) recommended degludec when hypoglycemia is a problem on other basal insulins.

Limitations Clinicians Should Weigh

The trial population was 85% insulin-experienced and 86% had established CVD. Extrapolation to younger, lower-risk, insulin-naive patients requires caution. DEVOTE tells you degludec is cardiovascularly safe in high-risk patients. It does not confirm superiority for MACE reduction in any population.

Median follow-up was under two years. Longer-term cardiovascular effects remain uncharacterized by RCT data. The DEVOTE extensions (DEVOTE 3, DEVOTE 5) examined day-to-day glycemic variability and hypoglycemia patterns but did not extend the primary MACE endpoint.

Glargine U100 was the comparator, not glargine U300 (Toujeo). The BRIGHT trial and CONCLUDE trial compared degludec to glargine U300 directly; results suggest similar hypoglycemia profiles between these two second-generation analogs. DEVOTE does not establish degludec superiority over U300.

Background therapy was heterogeneous. Some participants were on SGLT2 inhibitors or GLP-1 RAs with their own cardiovascular benefits. The trial was not powered to detect interaction effects with these agents.

Patients Who Differ From the Trial Population

For insulin-naive patients without CVD, DEVOTE provides safety reassurance but no specific cardiovascular advantage. The hypoglycemia benefit still applies based on phase 3 data (BEGIN trials), but the MACE data cannot be extrapolated to a fundamentally different risk profile.

For patients already on glargine U300 without hypoglycemia issues, DEVOTE provides no reason to switch. The relevant comparison there is CONCLUDE, which found no significant difference in severe hypoglycemia between degludec and U300 at 88 weeks.

For elderly patients with impaired hypoglycemia awareness, DEVOTE's nocturnal hypoglycemia data carries outsized relevance. A 53% reduction in severe nocturnal events is clinically meaningful for a population where a single severe episode can trigger falls, fractures, or loss of independence.

The Practice-Level Takeaway

DEVOTE moved degludec from "premium basal insulin with theoretical advantages" to "basal insulin with cardiovascular safety data and a proven hypoglycemia reduction in high-risk patients." The clinical implication is specific: when choosing a basal insulin for a patient with type 2 diabetes and established cardiovascular disease or recurrent hypoglycemia, degludec has trial-level evidence that glargine U100 does not match on the hypoglycemia axis.

This is not a mandate to switch stable, well-controlled patients. It is evidence that, for the right patient profile, degludec offers a quantifiable safety margin during sleep hours when patients cannot self-rescue.

Frequently asked questions

›

References

Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017;377(8):723-732. PubMed
Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the ADA and EASD. Diabetes Care. 2018;41(12):2669-2701. PubMed
Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Eur Heart J. 2020;41(2):255-323. PubMed
Tresiba (insulin degludec) Prescribing Information. Novo Nordisk. Revised 2019. FDA Label
Philis-Tsimikas A, Klonoff DC, Engberg S, et al. CONCLUDE: A Trial Comparing Degludec vs Glargine U300 in Insulin-Treated T2D. Diabetes Care. 2020;43(7):1507-1515. PubMed